← Leaderboards
Qiping Feng
Vanderbilt University Medical Center
$6,581,213
Attributed
$8,324,142
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,324,142 · 5
By mechanism
R01$7,449,600 · 4
R56$874,542 · 1
Top collaborators
- Wei-Qi Wei4 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Alexander Bick$5,781,681
- Michael Rutledge Debaun$40,846,229
- Wei-Qi Wei$9,737,275
- Douglas Ruderfer$8,775,014
- Colin George Walsh$3,971,490
Others in their field
Top investigators on “Biobank”
- Leonard Freedman · Leidos Biomedical Research, Inc.$247,215,881
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Peter J O'Dwyer · University Of Pennsylvania$120,526,242
- David Heimbrook · Leidos Biomedical Research, Inc.$115,298,400
- Praduman Jain · Vignet, Inc.$102,576,382
- Lynn Briscoe · Leidos Biomedical Research, Inc.$95,456,386
Research focus
BiobankNovel TherapeuticsPharmaceutical PreparationsDatabasesElectronic Health RecordLdl Cholesterol LipoproteinsDrug DevelopmentGenesVariantCoronary Heart DiseaseGenetic ResearchNew Therapeutic TargetGenetic VariantPhenotypeCause Of DeathGenotypeAdverse EffectsLinkDrug RepurposingGeneticLong-Term EffectsData SetDiabetes RiskAcademic Medical Centers
Grant awards (13)
Systematically screening and validating drug repurposing candidates for Alzheimer's Disease and Related Dementias$874,857
R01 · FY2025 · AG
Targeting Residual ASCVD Risk by Integrating Genetics and Clinical Data$861,667
R01 · FY2025 · HL
Genetics and Triglycerides: opportunities for new approaches to identify therapies$776,673
R01 · FY2025 · HL · contact PI
Targeting Residual ASCVD Risk by Integrating Genetics and Clinical Data$874,792
R01 · FY2024 · HL
Systematically screening and validating drug repurposing candidates for Alzheimer's Disease and Related Dementias$874,542
R56 · FY2024 · AG
Genetics and Triglycerides: opportunities for new approaches to identify therapies$761,139
R01 · FY2024 · HL · contact PI
Genetics and Triglycerides: opportunities for new approaches to identify therapies$776,673
R01 · FY2023 · HL · contact PI
Genetics and Triglycerides: opportunities for new approaches to identify therapies$819,698
R01 · FY2022 · HL · contact PI
Pleiotropy of PCSK9 Inhibition$339,965
R01 · FY2020 · GM · contact PI
Pleiotropy of PCSK9 Inhibition$339,965
R01 · FY2019 · GM · contact PI
Pleiotropy of PCSK9 Inhibition$339,965
R01 · FY2018 · GM · contact PI
Pleiotropy of PCSK9 Inhibition$346,535
R01 · FY2017 · GM · contact PI
Pleiotropy of PCSK9 Inhibition$337,671
R01 · FY2016 · GM · contact PI